Depression is the leading cause of disability worldwide and is associated with a 10-year reduction in life expectancy.
1,2 Achieving and maintaining remission, the goals of treatment for this recurrent disease, improves functioning, reduces suicide risk, and leads to greater clinical stability.
3 Patients who have not responded to at least 2 different antidepressants in the current depressive episode are considered to have treatment-resistant depression (TRD).
4 Patients with treatment-resistant major depressive disorder (MDD) experience relapse at a higher rate than do those with treatment-responsive MDD. Even when patients with TRD respond to treatment, the overall relapse rate while continuing treatment with the same antidepressant is high after 2 (65%; within 3.1 months) and 3 failed trials (71.1%; within 3.3 months).
3 There is a substantial unmet need for effective treatments that can sustain antidepressant benefits for the population with TRD.